In a positive turn for investors, Cross Country Healthcare, Inc. (CCRN) has been upgraded to an “Outperform” rating by Michael Piccolo of Wedbush on March 19, 2026, reflecting a bullish outlook for the company in a challenging market environment. With a current share price of $9.35 and a price target of $15, this upgrade signals significant upside potential, inviting both current and prospective investors to re-evaluate the stock’s viability in their portfolios.
Recent Price Action
Cross Country Healthcare has experienced notable price movements in recent trading sessions. The stock closed at $9.35, reflecting a $0.49 increase or approximately 5.53% in a single day of trading. Over the past year, the stock has encountered substantial volatility, with a 52-week high of $18.04 and a low of $9.35, indicating a wide trading range that has generated significant investor interest. The average daily trading volume hovered around 611,794 shares, with recent sessions witnessing nearly 630,757 shares exchanged. The market capitalization stands at approximately $306 million, and the stock shows a beta of 0.395, suggesting that it is relatively less volatile than the broader market, which could appeal to more risk-averse investors.
Historical Performance
Analyzing Cross Country Healthcare’s performance over varying timeframes reveals a complex picture. Over the past 30 days, the stock has shown a modest gain of 9.38%, yet its quarterly performance remains under pressure with a decline of 30.67%. The longer-term view is more concerning, with a staggering 51.71% drop over the past year, reflecting ongoing challenges within the healthcare staffing sector. Weekly volatility stands at 4.79%, while monthly volatility is somewhat lower at 3.95%. This volatile backdrop highlights the need for caution among investors, as market forces continue to shape the narrative around CCRN.
Earnings Analysis
In its latest earnings report released on November 12, 2025, Cross Country Healthcare posted an earnings per share (EPS) of $0.03, falling short of analysts’ expectations of $0.04. The reported EPS resulted in a surprise factor of -25%, mirroring a similar trend from the prior quarter, where the company also reported an EPS of $0.03 against an estimate of $0.04. This persistent undershooting raises concerns about the company’s earnings quality and predictability moving forward, suggesting that operational challenges may be impacting financial performance.
Analyst / Consensus View
The consensus among analysts appears cautiously optimistic despite the recent struggles in earnings performance. Currently, there are three ratings on Cross Country Healthcare, with two analysts recommending a “Buy” and one maintaining a “Hold.” The average price target stands at approximately $13.33, with a range from $11 to the newly upgraded $15, reflecting a blend of cautious optimism and acknowledgment of the risks that the company faces. Wedbush’s recent upgrade to “Outperform” further solidifies a more favorable outlook among analysts, particularly given the potential for recovery in the healthcare staffing industry.
Stock Grading or Fundamental View
Cross Country Healthcare currently holds a Stocks Telegraph Grade of 39, a metric that provides a comprehensive overview of the company’s financial health and market positioning. This grade suggests that while there is some fundamental strength, challenges remain that could impact growth. Investors should find value in the company’s leadership in healthcare staffing solutions; however, caution is warranted given the ongoing volatility and performance issues.
Conclusion
For investors considering a position in Cross Country Healthcare, the stock appears suited for those with a medium-to-long-term horizon who are willing to accept higher risk for potential upside. The recent rating upgrade from Wedbush suggests that there may be opportunities for growth as the company navigates its operational challenges. However, the significant risks—evidenced by recent earnings misses and staggering annual declines—indicate that investors should remain vigilant. CCRN may be a suitable option for those looking to capitalize on a potential recovery in the healthcare sector, but careful assessment of the ongoing volatility and overall market conditions is essential.